Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-10-03
2009-11-24
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S004000, C435S007210, C435S007230, C702S020000
Reexamination Certificate
active
07622253
ABSTRACT:
Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.
REFERENCES:
patent: 4586546 (1986-05-01), Mezei et al.
patent: 5561058 (1996-10-01), Gelfand et al.
patent: 5618703 (1997-04-01), Gelfand et al.
patent: 5693517 (1997-12-01), Gelfand et al.
patent: 5876978 (1999-03-01), Willey et al.
patent: 5916524 (1999-06-01), Tisone
patent: 5998768 (1999-12-01), Hunter et al.
patent: 5999209 (1999-12-01), Hunter et al.
patent: 6005664 (1999-12-01), Korenberg et al.
patent: 6036920 (2000-03-01), Pantoliano et al.
patent: 6037129 (2000-03-01), Cole et al.
patent: 6087098 (2000-07-01), McKiernan et al.
patent: 6088100 (2000-07-01), Brenan et al.
patent: 6154707 (2000-11-01), Livak et al.
patent: 6203759 (2001-03-01), Pelc et al.
patent: 6214293 (2001-04-01), Pantoliano et al.
patent: 6235520 (2001-05-01), Malin et al.
patent: 6300073 (2001-10-01), Zhao et al.
patent: 6358679 (2002-03-01), Heid et al.
patent: 6373726 (2002-04-01), Russell et al.
patent: 6406891 (2002-06-01), Legerski
patent: 6436677 (2002-08-01), Gu et al.
patent: 6448089 (2002-09-01), Vuong
patent: 6472218 (2002-10-01), Stylli et al.
patent: 6485917 (2002-11-01), Yamamoto et al.
patent: 6586257 (2003-07-01), Vuong
patent: 6638483 (2003-10-01), Vuong
patent: 6730883 (2004-05-01), Brown et al.
patent: 6814933 (2004-11-01), Vuong
patent: 6825927 (2004-11-01), Goldman et al.
patent: 6852986 (2005-02-01), Lee et al.
patent: 2001/0049134 (2001-12-01), Lee et al.
patent: 2002/0090320 (2002-07-01), Burow et al.
patent: 2002/0098593 (2002-07-01), Nelson et al.
patent: 2002/0098598 (2002-07-01), Coffen et al.
patent: 2002/0137667 (2002-09-01), Chuenkova et al.
patent: 2003/0027179 (2003-02-01), Heid et al.
patent: 2003/0087446 (2003-05-01), Eggers
patent: 2003/0108868 (2003-06-01), Richards
patent: 2003/0109060 (2003-06-01), Cook et al.
patent: 2003/0118483 (2003-06-01), Militzer et al.
patent: 2003/0124539 (2003-07-01), Warrington et al.
patent: 2003/0136921 (2003-07-01), Reel
patent: 2003/0149639 (2003-08-01), Stolakis et al.
patent: 2003/0190652 (2003-10-01), De La Vega et al.
patent: 2003/0202637 (2003-10-01), Yang
patent: 2003/0205681 (2003-11-01), Modlin
patent: 2003/0207464 (2003-11-01), Lemmo et al.
patent: 2003/0215957 (2003-11-01), Lemmo et al.
patent: 2003/0219760 (2003-11-01), Gordon et al.
patent: 2004/0014238 (2004-01-01), Krug et al.
patent: 2004/0018506 (2004-01-01), Koehler et al.
patent: 2004/0057870 (2004-03-01), Isaksson et al.
patent: 2004/0061071 (2004-04-01), Dorsel
patent: 2004/0131505 (2004-07-01), Koeda
patent: 2004/0202577 (2004-10-01), McNeil et al.
patent: 2004/0203047 (2004-10-01), Caren et al.
patent: 2004/0203164 (2004-10-01), Cizdziel et al.
patent: WO 2004/051218 (2004-06-01), None
Rosenvald et al., New Eng J of Med, vol. 346, p. 1937, 2002.
Drillenburg, P. et al; CD44 expression predicts disease outcome in localized large B cell lymphoma; Leukemia; pp. 1446-1455; (1999).
Hans, C.P. et al.; “Confirmation of the molecular classification of diffuse large B-cell lymphoma by imunohistochemistry using a tissue microarray”; Blood; vol. 103, No. 1; Sep. 22, 2003; pp. 275-282.
Lossos, I.S. et al.; “Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes”; The New England Journal of Medicine; vol. 350, No. 18; Apr. 29, 2004; pp. 1828-1837.
Wright, G. et al.; “A gene expression based method to diagnose clinically distinct subgroups of large B cell lymphoma”; Proceedings of the National Academy of Sciences of the 2003 United States of America; vol. 100, No. 17, Aug. 19, 2003.
Adida et al., “Prognostic significance of surviving expression in diffuse large B-cell lymphomas”, Blood; vol. 96, No. 5, pp. 1921-1925, 2000.
Alizedeh et al., “Distinct Types of Diffuse Large B-cell Lymphoma Identified by Gene Expression Profiling”, Nature, vol. 403, pp. 503-511, 2000.
Barrans et al., “Germinal center phenotype and bcl 1-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma”, Blood, vol. 99, No. 4, pp. 1136-1143, 2002.
Boehm et al., “The rhombotin family of cysteine-rich LIM-domain oncogenes: Distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13”, Proc. Natl. Acad. Sci. U S A, vol. 88, No. 10, pp. 4367-4371, 1991.
Cattoretti et al., BCL-6 Protein is Expressed in Germinal-Center B Cells, Blood, vol. 86, No. 1, pp. 45-53, 1995.
Chang et al., “BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor”, Proc. Natl. Acad. Sci. U S A, vol. 93, pp. 6947-6952, 1996.
Dent et al., “T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6”, Proc. Natl. Acad. Sci. U S A, vol. 95. pp. 13623-13628, 1998.
Freeman et al., “Quantitative RT-PCR: Pitfalls and Potential”, BioTechniques, vol. 26, No. 1, pp. 112-125, 1999.
Gascoyne et al., “Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma”, Blood, vol. 90, No. 1, pp. 244-251, 1997.
Harris et al., “A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group”, vol. 84, No. 5, pp. 1361-1392, 1994.
Hermine et al., “Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma” , Blood, vol. 87, No. 1, pp. 265-272, 1996.
Hill et al.,“Prognostic Significance of BCL-2 Expression and bcl-2 Major Breakpoint Region Rearrangement in Diffuse Large Cell Non-Hodgkin's Lymphoma: A British National Lymphoma Investigation Study”, Blood, vol. 88, No. 3, pp. 1046-1051, 1996.
Ichikawa et al., “Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma”, New England J Med, vol. 337, No. 8, pp. 529-534, 1997.
Kaiser, “Seeking the Cause of Induced Leukemias in X-SCID Trial”, Science, vol. 299, p. 495, 2003.
Kerckaert et al., “LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas”, Nat. Genet, vol. 5, pp. 66-70, 1993.
Koduru et al., “Correlation Between Mutation in P53, p 53 Expression, Cytogenetics, Histologic Type, and Survival in Patients With B-Cell Non-Hodgkin's Lymphoma”, Blood, vol. 90, No. 10, pp. 4078-4091, 1997.
Kramer et al., “Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma”, Blood, vol. 92, No. 9, pp. 3152-3162, 1998.
Kramer et al., “Clinical Significance of be12 and p53 Protein Expression in Diffuse Large B-Cell Lymphoma: A Population-Based Study”, J. Clin Onco, vol. 14, No. 7, pp. 2131-2138, 1996.
Krenacs et al., “Transcription Factor B-Cell-Specific Activator Protein (BSAP) Is Differentially Expressed in B Cells and in Subsets of B-Cell Lymphomas”, Blood, vol. 92, No. 4, pp. 1308-1316, 1998.
Livak et al., “Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-ΔΔcT Method”, Methods, vol. 25, pp. 402-408, 2001.
Lossos et al.,“HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma”, Blood, vol. 101, No. 2, pp. 433-440, 2003.
Lossos et al., “Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma”, Blood, vol. 98, No. 4, pp. 945-951, 2001.
Lossos et al., “Diffuse Large B-Call Lymphoma: I
Alizadeh Ash A.
Botstein David
Levy Ronald
Lossos Izidore S.
Tibshirani Robert J.
Harness & Dickey & Pierce P.L.C.
Helms Larry R.
Yao Lei
LandOfFree
Classification of patients having diffuse large b-cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Classification of patients having diffuse large b-cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Classification of patients having diffuse large b-cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075493